NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT03747484 2025-03-06
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02584829 2022-03-22
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03988647 2021-08-09
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT02514824 2020-12-29
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00765193 2010-04-15
TBSE
Medical University of Graz
Phase NA Completed